Brainstem and cerebellar modulation of cardiovascular response and disease

• US 20030149450A1
• Filed: 02/03/2003
• Published: 08/07/2003
• Est. Priority Date: 02/01/2002
• Status: Abandoned Application

• Current Assignee: Marc R. Mayberg
• Original Assignee: Marc R. Mayberg
• Inventors: Mayberg, Marc R.
• Application Number:
  US10/357,161
• Publication Number:
  US 20030149450A1
• Time in Patent Office: Days
• US Class Current: 607/3
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth electrode stimulation, and localized infusion of agents to these regions.

Claims

1. An apparatus for modulating autonomic response in a vertebrate comprising:

a therapeutic delivery device positioned near a site of the hindbrain structure of the vertebrate for modulating the function of the hindbrain and a controller in communication with the therapeutic delivery device to enable it to deliver the therapy.

2. The apparatus of claim 1 wherein said therapeutic delivery device is an electrode electrically connected to said controller.

3. The apparatus of claim 1 wherein said therapeutic delivery device delivers a pharmaceutical reagent to a site of said hindbrain structure and is connected to said controller.

4. The apparatus of claim 1 further comprising a sensor that measures a cardiovascular state of said vertebrate and is electrically connected to said controller.

5. The apparatus of claim 1 wherein said electrode is at a site near the surface of said hindbrain structure.

6. The apparatus of claim 1 wherein said electrode is implanted in the body of said vertebrate at a site near said hindbrain structure.

7. The apparatus of claim 6 wherein said hindbrain structure is selected from the group consisting of the medulla and the cerebellum.

8. The apparatus of claim 6 wherein said hindbrain structure is selected from the group consisting of the nucleus tractus solitarius, the caudal ventrolateral medulla, and the rostral ventrolateral medulla.

9. The apparatus of claim 1 wherein said electrodes are coated or comprise a composition that promotes adherence and growth of endogenous tissue and cells with said therapeutic delivery device to maintain the position of said therapeutic delivery device within said tissue.

10. The apparatus of claim 6 wherein said hindbrain structure chosen from the group consisting of fastigial nuclei and vestibular nuclei.

11. A method of controlling the cardiovascular state of a patient comprising:

comparing the cardiovascular state of a patient to a normal cardiovascular state and delivering a therapy from a therapeutic delivery device in a sufficient amount to a hindbrain structure to return the vertebrate to the normal cardiovascular state.

12. The method of claim 11 further comprising the step of measuring the cardiovascular state of the patient with sensors chosen from the group consisting of pH, blood pressure, heart rate dissolved oxygen, and dissolved carbon dioxide.

13. The method of claim 11 further comprising calculating the cardiac output.

14. The method of claim 11 wherein said therapy is electrical stimulation near a hindbrain structure.

15. The method of claim 11 wherein the steps of comparing the cardiovascular state and delivering the therapy to the patient are performed in a closed loop.

16. The method of claim 11 wherein the steps of comparing the cardiovascular state and delivering the therapy to the patient are performed in a closed loop using fuzzy logic rules.

17. The method of claim 11 wherein multiple therapeutic delivery devices are used and are enabled in response to the results of the step of comparing the cardiovascular state of the patient to a normal state.

18. The method of claim 11 wherein the step of delivering a therapy is changing the output from the therapeutic delivery device to the hindbrain structure, wherein the output from the therapeutic delivery device is chosen from the group consisting of voltage, pulse width, pulse frequency, current, drug delivery rate, and drug concentration.

19. The method of claim 11 wherein the therapy is a drug chosen from the group consisting of clonidine, guanethidine, a vetatrum alkaloid, and alpha-blockers, or specific neural excitatory or inhibitory transmitters and their antagonists such as gamma-aminobutyric acid (GABA), glycine, norepinephrine, acetylcholine (Ach), or nitric oxide (NO), proteins or enymes which modify the metabolism, release, binding and re-uptake of neurotransmitters, and genes and gene products which regulate cellular processes related to neural transmission.

20. The method of claim 11 wherein the cardiovascular condition is selected from the group consisting of essential hypertension, hypotension (Shy-Drager), paroxysmal atrial tachycardia, and bradycardia.